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Several intracellular proteins are involved in mediating 
vesicular transport of protein and lipid cargo from the 
endoplasmic reticulum (ER) to the Golgi apparatus (GA) in 
eukaryotic cells. Errors in membrane trafficking between ER 
and GA have been implicated in brain disorders [1, 7], show-
ing that these processes are critical for neuronal biogenesis. 
An important protein in these processes is YIF1B, an intra-
cellular 314-residue transmembrane protein. Hippocampal 
neurons from Yif1B knockout (KO) mice showed that Yif1B 
is implicated in anterograde trafficking and Golgi architec-
ture [1], where depletion of Yif1b caused disorganization, 
fragmentation, and volume reduction of the GA in pyramidal 
neurons.
Here we describe six patients from five unrelated families 
presenting with profound developmental and motor delay 
with dystonia, dysphagia, hypotonia, epilepsy and micro-
cephaly, and homozygous truncating variants in YIF1B 
encountered by whole exome sequencing (WES), identify-
ing YIF1B as a novel disease gene in humans (Fig. 1, Sup-
plementary Fig. 1, Supplementary Table 1, online resource 
for detailed clinical information).
Clinical examinations revealed that all patients had 
an unremarkable pregnancy and birth, and no major dys-
morphic features. Hypotonia and global developmen-
tal delay were noticed in infancy with smiling and par-
tial babbling as their best achieved social and language 
skills. Motor development remained profoundly affected 
without head control, rolling or sitting. By age 2–3 years 
distal, limb choreiform movements started in four indi-
viduals which evolved into axial and limb dystonia with 
dyskinesia by the age of 4–8 years. Dystonia was unre-
sponsive to levodopa or carbidopa but partially improved 
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on trihexyphenidyl. Two individuals developed epileptic 
seizures at 6- to 8-months. EEG showed multiple bilat-
eral epileptiform discharges and abnormal background 
indicating diffuse dysfunction. Microcephaly was found 
in all but one individual. There were no exaggerated star-
tle, organomegaly or neurocutaneous stigmata. Hearing 
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was normal. One case presented with cortical blindness. 
Repeated MRI brain imaging showed mild thinning of the 
corpus callosum in the majority of cases without other 
structural abnormalities, with brain atrophy in one case 
(Fig. 1f). Other standard metabolic investigations in serum 
and liquor were unremarkable. Hence, all individuals with 
truncating YIF1B variants shared a similar phenotypical 
spectrum. All affected residues encountered were highly 
conserved and identified variants (c.186dupT:p.Ala64fs; 
c.360_361insACAT:p.Gly121fs; c.598G > T:p.Glu200*) 
were absent from gnomAD and other databases of healthy 
individuals with no other homozygous loss-of-function 
variants found (Supplementary Fig. 1b online resource).
YIF1B is widely expressed at mRNA and protein levels 
in all tissues including neuronal cells, in particular raphe 
neurons (Supplementary Figs. 2–4, online resource). Func-
tional and network analyses identified 171 genes that are 
co-regulated with YIF1B in over 46,000 human RNAseq 
samples (r ≥ 0.9), that were enriched in genes involved in 
neurological and development disorders, and nervous system 
development and function (p value < 0.01) (Supplementary 
Fig. 5a, b and Supplementary Tables 2, 3, online resource).
In rat, the YIF1B ortholog interacts with serotonin 
receptor 1 (5-HT1AR) which is a Gi/Go protein-coupled 
receptor in dendrites of serotonin neurons of the raphe 
nuclei. Co-localization of Yif1B and 5-HT1AR was 
observed in intermediate compartment small vesicles, 
showing Yif1B involvement in transient intracellular traf-
ficking and modulation of 5-HT1AR transport to dendrites 
[2, 3]. Hence, defects on Yif1B may lead to the impair-
ment of the physiological functioning of 5-HT1AR [4]. 
YIF1B also interacts with the lysosomal protein TAPL 
in humans [5]. In HeLa cells, overexpressing truncated 
YIF1B reduced TAPL’s lysosomal localization and co-
localization with truncated YIF1B in the cis-Golgi [6]. 
In addition, Yif1B interacts with Rab6, a recycle traffick-
ing protein. Therefore, alterations of this interaction may 
lead to aggregates’ accumulation in neurons, which has 
been reported to cause neurodegenerative diseases [1]. 
These findings show that to fulfill its biological func-
tion, YIF1B interacts with different proteins and controls 
their trafficking. Consequently, mutations affecting pro-
tein binding sites or subcellular localization of YIF1B are 
expected to cause trafficking deficiencies of its interaction 
partners.
Computational protein modelling of YIF1B predicted 
that the first ~ 68 residues form a cytosolic disordered 
region and indicated the presence of transmembrane 
helices in the remaining ~ 250 residues (Fig.  1e, Sup-
plementary Fig. 6a, b, online resource). The p.Gly121fs 
variant leads to the insertion of 31 non-related residues 
which are predicted to be unstructured (Supplementary 
Fig. 6a–c online resource). Although we cannot rule out 
that this variant might retain some capacity to insert into 
membrane, its biological function is most likely lost. The 
p.Ala63fs variant leads to the introduction of 12 unrelated 
residues following Pro62 before the stop codon, resulting 
in truncation before the first helix, indicating a complete 
loss of function. The variant p.Glu200* has 3.5 transmem-
brane helices missing, which is, therefore, predicted to be 
non-functional.
Hence, the reported disease phenotypes are corre-
sponding to the effects of a complete loss-of-function of 
YIF1B. Collectively, our data provide a demonstration of 
the importance of YIF1B in humans and argue that this 
gene is involved in a novel neurogenetic disorder. Fur-
ther functional studies are required to unravel the precise 
pathogenetic mechanisms of this novel disease entity.
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Fig. 1  a Pedigrees of six affected individuals from five families. b 
Sanger sequencing reveals segregation of the variants in the tested 
families. c An ROH was detected on chromosome 19 including 
YIF1B. d Scheme of YIF1B transcripts, affected exons, and result-
ing truncations. e 3D structural model for YIF1B. Helices are shown 
as cylinders, and the predicted molecular surface of the structured 
transmembrane portion of YIF1B is indicated. The flexible cytosolic 
region is shown in an arbitrary conformation. Protein regions retained 
in the variants are shown in magenta (p.Ala63fs) and magenta/cyan 
(p.Gly121fs) and magenta/cyan/green (p.Glu200*). The residues 
resulting from the frame shifts were not included (see Supplementary 
Figs.  2 and 3). f Brain MRI. Mild thinning of the corpus callosum 
was noted in all patients with the founder mutation
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